Janssens, Gladys N.
Daemen, Joost
Lemkes, Jorrit S.
Spoormans, Eva M.
Janssen, Dieuwertje
den Uil, Corstiaan A.
Jewbali, Lucia S. D.
Heestermans, Ton A. C. M.
Umans, Victor A. W. M.
Halfwerk, Frank R.
Beishuizen, Albertus
Nas, Joris
Bonnes, Judith
van de Ven, Peter M.
van Rossum, Albert C.
Elbers, Paul W. G.
van Royen, Niels http://orcid.org/0000-0001-6136-8640
Funding for this research was provided by:
ICIN Netherlands Heart Institute
Biotronik
AstraZeneca
Article History
Received: 23 September 2021
Accepted: 21 January 2022
First Online: 11 February 2022
Declarations
:
: The study protocol was approved by the IRB of the VU University Medical Center and ethics approval was obtained by the medical ethics committee of the VU University Medical Center, Amsterdam, the Netherlands, with approval number 2017.398. Informed consent was waived, as it was not achievable to obtain this from all patients of the large retrospective study cohort.
: The medical ethics committee approved that informed consent was waived, as it was not achievable to obtain this from all patients of the large retrospective study cohort. All authors consented for publication of the study.
: Prof. Dr. van Royen reports research grants from AstraZeneca, Abbott, Philips, Biotronik and an honorarium from Medtronic. Dr. Lemkes reports grants from Biotronik and Astrazeneca, during the conduct of the study. All other authors declare no competing interests with regard to the study.